Phio Pharmaceuticals Corp. · NASDAQ:PHIO
Phio Pharmaceuticals — RXi Pharmaceuticals — Investor Presentation (March 2018)
14 slides from Phio Pharmaceuticals's investor presentation, Mar 27, 2018
Slide 1: Developing the Next Generation of Immuno-Oncology Therapeutics
RXi Pharmaceuticals NASDAQ: RXII Dr. Geert Cauwenbergh, Dr. Med. Sc. President and CEO www.rxipharma.com Developing the Next Generation of Immuno-Oncology Therapeutics Exhibit 99.1
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believes,” “anticipates,” “plans,” “expects,” “indicates,” “will,” “intends,” “potential,” “suggests” and similar expressions ar
Slide 3: RXi is Developing the Next Generation of Immuno-Oncology Therapeutics
RXi is Developing the Next Generation of Immuno-Oncology Therapeutics RXi’s therapeutic platform can improve existing treatment paradigms with enhanced tumor killing activity to attack cancer. Cancer is a global killer. Existing treatment approaches have inherent limitations and serious side effects
Slide 4: sd-rxRNA self-delivering RNAi therapeutic platform
sd-rxRNA: Next Generation of Immuno-Oncology Therapeutics RXi has developed a self-delivering RNAi (sd-rxRNA®) therapeutic platform sd-rxRNA can penetrate immune cells, where antibodies fall short, and block the expression of disease proteins
Slide 5: sd-rxRNA: Weaponizing Therapeutic Immune Cells to Treat Cancer
TILs sd-rxRNA Checkpoint inhibition Enhancing long-term survival and “metabolic fitness” of immune cells Blood Cancers Solid Tumors Enhancing long-term survival and “metabolic fitness” of immune cells sd-rxRNA: Weaponizing Therapeutic Immune Cells to Treat Cancer Immune Cells Precise and selective p
Slide 6: sd-rxRNA: Attack Cancer using Adoptive Cell Transfer Method
sd-rxRNA: Attack Cancer using Adoptive Cell Transfer Method Improving Immune Effector Cells with RNAi sd-rxRNA to Improve Cell Activity and Longevity sd-rxRNA Enhances Tumor Killing Activity of Immune Cells
Slide 7: Demonstrated Broad Applicability of sd-rxRNA
Demonstrated Broad Applicability of sd-rxRNA Number one Number two Number three Number one Number two Number three Human T Cells Engineered T Cells TILs for ovarian cancer or melanoma HSCT for modulation of GvHD g/d T cells CAR T TCR Checkpoint inhibition and optimization for persistence and fitness
Slide 8: Internal Development Pipeline
Internal Development Pipeline INTERNAL Target Indication Disc. Preclin Clinical RXI-762 PD-1* Solid Tumors RXI-804 TIGIT* Solid Tumors Other checkpoints Multiple* Solid Tumors Cell differentiation Multiple* Blood cancers and Solid Tumors *In ACT Developing the Next Generation of Immuno-Oncology Ther
Slide 9: Collaborations with Leading Cancer Centers and Cancer Focused Biopharma
Collaborations with Leading Cancer Centers and Cancer Focused Biopharma EXTERNAL SCOPE STATUS TILs sd-rxRNA against various cancer types (incl. melanoma, ovarian cancer) Pilot study results are promising; preclinical studies underway. Oncology models sd-rxRNA technology platform for use in cancer tr
Slide 10: RXII: Positioned for Success with Safe and Proven sd-rxRNA Platform
RXII: Positioned for Success with Safe and Proven sd-rxRNA Platform Improved development landscape for cancer therapeutics Active government support (Cancer Moonshot) Expedited reviews by FDA Clinically proven safety of sd-rxRNA by direct local injection The field of immunotherapy is evolving toward
Slide 11: Near Term Goal: Enter Clinical Development 12-18 Months
Near Term Goal: Enter Clinical Development 12-18 Months - - INDICATION Preclinical data available to support selection of target indication PHENOTYPIC DATA In-vitro efficacy and safety data available for regulatory submission STUDY START Approval received for first patient dosing MONTH 3 MONTH 6 MON
Slide 12: Competitive Landscape RXi: Primed for Success
Competitive Landscape RXi: Primed for Success 1https://www.genengnews.com/the-lists/top-10-immuno-oncology-collaborations/77900887 Current I-O Treatments Yield Billions1 Large Valuation of Companies Using Lesser Technologies to Improve ACT Current I-O Treatments Yield Billions Competition has signif
Slide 13: Financial Overview
Financial Overview Cash and cash equivalents* (a/o 12/31/2017) ~$3.6M Burn rate ~$2.0-$2.5M/quarter Cash runway (Assuming current NASDAQ limitations with use of equity line) Q2/Q3 2018 Cash runway (Assuming full use of $15M equity line available) Q4 2019 Common shares outstanding (a/o 3/15/2018) ~2.
Slide 14: RXII: Developing the Next Generation of Immuno-Oncology Therapeutics
RXII: Developing the Next Generation of Immuno-Oncology Therapeutics Large Deals with Early Pipelines Gilead/Kite: $11B Celgene/Juno: $9B Multi-billion market potential Potential 3-5x Return on Investment 12-18 months New Class of Powerful Therapeutics First RNAi drug approval expected in 2018 Prove
RXi Pharmaceuticals — Investor Presentation (March 2018) on 6ix